High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key

Terlizzi, Mario; Bossi, Alberto

doi:10.1016/j.euros.2021.07.010

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMRT with long-term ADT is a standard treatment option for localized high-risk prostate cancer patients. The effect of RT with ADT on cancer-specific survival and OS has been demonstrated by studies (11,12). In the EORTC 22863, the 10-year disease-free survival (48% vs. 23%) and OS (58% vs. 40%) were improved with a combination therapy compared with RT alone.…”

Section: Discussionmentioning

confidence: 97%

Treatment outcomes in high-risk prostate cancer: a single-centre experience

ADAŞ

2022

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

Aim: The aim of that study was to evaluate the treatment results of patients with high-risk prostate cancer who received image-guided intensity-modulated radiotherapy with curative intent. Material and Method: Patients who underwent curative radiotherapy (RT) for high-risk prostate cancer were evaluated retrospectively in our clinic from April 2010 to April 2021. Demographics, prostate specific antigen (PSA) levels, gleason score (GS), the TNM stage of the tumor, and the success of treatment and complications were noted. Results: Eighty-two patients were evaluated. The mean follow-up time was 39.1 months. The mean age was 71.2±6.2 (range 50-84 years) years. The mean PSA levels of the patients was 41.1±33.8, and the median was 27 ng/ml (range 8-129 ng/ml). The mean GS of the patients was 8.3±0.6, and the median was 8 (range 7-10). The mean overall survival (OS) rate was 75.6%; survival rates for 24 months and 36 months were 91.1% and 80.4% respectively. The progression-free survival (PFS) was found to be 62.8%. Moreover, the PFS time was found to be 66,6 months. Twenty-four months and 36 months PFS rates were 83.6% and 65.4%, respectively. Conclusion: Intensity-modulated radiotherapy (IMRT) combined with androgen deprivation therapy is a safe and effective treatment modality for elderly patients with high-risk prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

Treatment outcomes in high-risk prostate cancer: a single-centre experience

ADAŞ

2022

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

show abstract

“…PrCa that has progressed to this stage is termed castration resistant prostate cancer (CRPC), and the mean survival for patients with this stage of disease is 14 months. Challenges to therapeutic modalities outside of ADT often involve targeting inefficiency and limited dose tolerance due to toxicity, thus further exploration and development of therapeutics is needed, with an interest in the field on multimodal therapeutics and development of new targeting strategies for more efficient and less toxic therapeutic delivery (Chang et al, 2014;Terlizzi and Bossi, 2022).…”

Section: Introductionmentioning

confidence: 99%

Poly I:C-priming of adipose-derived mesenchymal stromal cells promotes a pro-tumorigenic phenotype in an immunocompetent mouse model of prostate cancer

Rivera-Cruz,

Kumar,

Figueiredo

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Introduction: Mesenchymal stromal cells (MSC) are envisioned as a potential cellular vehicle for targeted cancer therapies due to their tumor tropism and immune permissiveness. An obstacle in their use is the duality in their interactions within tumors, rendering them pro-tumorigenic or anti-tumorigenic, in a context dependent manner. MSC preconditioning, or priming, has been proposed as a strategy for directing the effector properties of MSC at tumor sites.Methods: We primed human MSC derived from adipose tissues (ASC), a clinically advantageous MSC source, utilizing toll-like receptor agonists. Subsequently, we explored the consequences in tumor progression and transcriptome upon the interaction of tumor cells with primed or unprimed ASC in an in vivo model of prostate cancer, the second most common cancer and second leading cause of cancer related death in men in the USA.Results and discussion: In the studied model, poly I:C-primed ASC were found to significantly accelerate tumor growth progression. And while unprimed and LPS-primed ASC did not exert a significant effect on tumor growth at the macroscopic level, gene expression analyses suggested that all treatments promoted distinct modulatory effects in the tumor microenvironment, including altered modulation of angiogenesis, and immune response processes. However, the effects resulting from the collective interaction across these processes must be sufficiently skewed in a pro-tumorigenic or anti-tumorigenic direction for evidence of tumor progression modulation to be detectable at the macroscopic level. Our study highlights potential MSC-tumor microenvironment interactions that may be leveraged and should be considered in the development of cancer therapeutics utilizing MSC.

show abstract

High-risk and Oligometastatic Prostate Cancer: Current Treatment Paradigms

Mandal,

Singh

2024

UroCancer Clinics of India

View full text Add to dashboard Cite

Summary Over the past decade or so with the treatment of high risk and oligometastatic disease has undergone a paradigm shift. Improvements in surgical techniques especially the robot assisted surgeries and better radiation techniques have ensured a good quality of life with maintained oncological outcomes. Further to it development and better understanding the disease biology have ensured good outcomes even in high grade cancers. This comprehensive overview delves into the management of high-risk prostate cancer and oligometastatic prostate cancer, addressing their definitions, diagnostic workup, and treatment modalities. Essentially managing high-risk and oligometastatic prostate cancer requires a multidisciplinary approach, integrating surgery, radiation, and systemic therapies.

show abstract

High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key

Cited by 3 publications

References 10 publications

Treatment outcomes in high-risk prostate cancer: a single-centre experience

Treatment outcomes in high-risk prostate cancer: a single-centre experience

Poly I:C-priming of adipose-derived mesenchymal stromal cells promotes a pro-tumorigenic phenotype in an immunocompetent mouse model of prostate cancer

High-risk and Oligometastatic Prostate Cancer: Current Treatment Paradigms

Contact Info

Product

Resources

About